logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
23/10/2026
Apple wins copyright case over 'Servant' with director M. Night Shyamalan.
Latest
3 m ago
Brent crude oil broke through $113 per barrel, up 3.87% on the day.
3 m ago
London stocks fell on the 22nd.
4 m ago
JPMorgan: A merger with Tesla could be SpaceX's ticket into the S&P 500
6 m ago
The Nagqu Military Sub-district of the Tibet Military District dispatched 98 officers and soldiers to the earthquake-stricken area.
11 m ago
Moderna (MRNA.O) fell nearly 25% at one point during intraday trading on Thursday, while Merck (MRK.N) dropped 3.7%. Trial data for an experimental cancer vaccine jointly developed by the two companies was suspected to have been published ahead of schedule on the medical website Oncology Central and was subsequently taken down; it had been scheduled for release on Saturday at the European Society for Medical Oncology (ESMO) Congress. According to the briefly disclosed data, the vaccine used in combination with Merck's anticancer drug Keytruda can reduce the risk of melanoma recurrence or death. The two companies had previously announced that the Phase 3 trial met its primary goals but had not yet published detailed results.
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.